Alimera Sciences, Inc. (ALIM)

NASDAQ: ALIM · IEX Real-Time Price · USD
3.890
-0.010 (-0.26%)
Mar 28, 2024, 11:41 AM EDT - Market open

Company Description

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.

It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors.

It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases.

Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alimera Sciences, Inc.
Alimera Sciences logo
Country United States
Founded 2003
IPO Date Apr 22, 2010
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 154
CEO Richard S. Eiswirth Jr.

Contact Details

Address:
6310 Town Square, Suite 400
Alpharetta, Georgia 30005
United States
Phone 678-990-5740
Website alimerasciences.com

Stock Details

Ticker Symbol ALIM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001267602
CUSIP Number 016259202
ISIN Number US0162592028
Employer ID 20-0028718
SIC Code 2834

Key Executives

Name Position
Richard S. Eiswirth Jr. Chief Executive Officer and Director
David R. Holland Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications and Managed Markets
Dr. Philip Ashman Ph.D. President of International Operations
Todd Michael Wood President of U.S. Operations
Elliot Maltz CPA Chief Financial Officer and Treasurer
Jason Werner Chief Operating Officer
Christopher S. Visick Vice President, General Counsel and Secretary
Dr. David Dyer M.D. Chief Retina Specialist

Latest SEC Filings

Date Type Title
Mar 8, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 8, 2024 10-K Annual Report
Mar 7, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 9, 2024 S-8 Securities to be offered to employees in employee benefit plans